首页> 外文OA文献 >352 Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab

【2h】

352 Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab

机译：352从头饰（SCCHN）的鳞状细胞癌（SCCHN）扩展队列的癌症癌（Scchn）的癌症癌的临床数据更新了持续的pH1 / 1B的延期研究（以前IPI-549）与Nivolumab的组合

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Ezra Cohen; Michael Postow; Ryan Sullivan; David Hong; Heather Yeckes-Rodin; Jerry McCarter; Nora Zizlsperger; Jeffery Kutok; Brenda O’Connell; Kara Page; Jennifer Roberts; Halle Zhang; Bartosz Chmielowski;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 352?Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab [J] . Ezra Cohen, Michael Postow, Ryan Sullivan, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：352？从头部和颈部（SCCHN）的鳞状细胞癌（SCCHN）扩展队列的癌症癌的临床数据更新了与Nivolumab的持续pH1 / 1B研究的肿瘤和颈部（SCCHN）扩展队列的延期研究（以前IPI-549）组合
2. 434?Updated clinical data from the melanoma expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab [J] . Michael Postow, Ryan Sullivan, Ezra Cohen, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：434？从黑色素瘤扩张队列的临床数据更新了持续的pH1 / 1B研究，Egonelisib（以前IPI-549）与Nivolumab组合
3. Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups [J] . Ferris R. L., Blumenschein G. R., Fayette J., International Journal of Radiation Oncology, Biology, Physics . 2018,第5期

机译：来自Checkmate 141的两年更新：患有Nivolumab（Nivo）的结果对核和颈部（SCCHN）的复发性或转移性（R / M）鳞状细胞癌（SCCHN）中的反复化或调查仪的选择（IC）
4. Up-Regulation of Enhancer of Zeste Homolog 2 Is Associated Positively With Cyclin Dl Overexpression and Poor Clinical Outcome in Head and Neck Squamous Cell Carcinoma [C] . Wei Cao, Zhien Feng, Zhibin Cui, Academic Committee conference of Shanghai key lab of stomatology . 2011

机译：Zeste同源2的增强子的上调与Cyclin Dl过度表达和头颈部鳞状细胞癌的不良临床结果呈正相关。
5. Inflammatory mechanisms of chemokine receptor 7 expression in metastatic squamous cell carcinoma of the head and neck (SCCHN). [D] . Mburu, Yvonne K. 2011

机译：趋化因子受体7在头颈部转移性鳞状细胞癌（SCCHN）中表达的炎症机制。
6. Active8: a randomized double-blind placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) [O] . Robert L Ferris, Ezra Cohen, Kelly Gash, 2014

机译：Active8：一项化疗西妥昔单抗联合TLR8激动剂VTX-2337对头颈部复发或转移性鳞状细胞癌（SCCHN）患者进行的随机双盲安慰剂对照研究
7. Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups [O] . R.L. Ferris, G.R. Blumenschein, J. Fayette, 2018

机译：来自Checkmate 141的两年更新：患有Nivolumab（Nivo）的结果对核和颈部（SCCHN）的复发性或转移性（R / M）鳞状细胞癌（SCCHN）中的反复化或调查仪的选择（IC）

352 Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab

著录项

相似文献

相关主题

期刊订阅